Short CV/Education and training

  • 1977 – 1981
    Studied pharmacy at LMU Munich, Germany

  • 1982 – 1984
    Doctoral studies in natural science at the Institute of Pharmaceutical Biology, LMU Munich

  • 1982
    Pharmacist's licence

  • 1984
    Doctor of natural science (Dr rer. nat.)

  • 1991
    Habilitation (postdoctoral qualification) in pharmacology, toxicology and pharmacy

  • 1985 – 1987
    Postdoc with a German Research Foundation (DFG) research fellowship in the Department of Biochemistry, University of California, Los Angeles, USA

  • 1988 – 1991
    Academic councillor (temporary appointment) at the Institute of Pharmacology, Toxicology and Pharmacy, Faculty of Veterinary Medicine, LMU Munich

  • 1991
    Private lecturer of clinical pharmacology and pharmacy, LMU Munich

  • 1991
    Visiting researcher at the Molecular Genetics Laboratory, nstitut de recherches cliniques de Montréal, Canada

  • 1991 – 1994
    Group leader at the Institute of Pharmacology, Toxicology and Pharmacy, Faculty of Veterinary Medicine, LMU Munich

  • 1993
    Offer of a professorship in "pharmaceutical biochemistry" at Heidelberg University

  • 1994
    C3 professorship of "the preparation and prescribing of medicinal drugs", LMU Munich

  • 1998
    Professor's chair in "pharmaceutical biology", Faculty of Pharmacy, LMU Munich

Selected publications

  • Borowiak M et al. Photoswitchable Inhibitors of Microtubule Dynamics Optically Control Mitosis and Cell Death. In: Cell. 2015 Jul 16;162(2):403-11

  • Liebl J et al. Cdk5 controls lymphatic vessel development and function by phosphorylation of Foxc2. In: Nat Commun. 2015 Jun 1;6:7274.

  • Schneider LS et al. Vacuolar-ATPase Inhibition Blocks Iron Metabolism to Mediate Therapeutic Effects in Breast Cancer. In: Cancer Res. 2015 Jul 15;75(14):2863-74.

  • Ehrlich SM et al. Targeting cyclin dependent kinase 5 in hepatocellular carcinoma--A novel therapeutic approach. In: J Hepatol. 2015 Jul;63(1):102-13.

  • Eirich J et al. A small molecule inhibits protein disulfide isomerase and triggers the chemosensitization of cancer cells. In: Angew Chem Int Ed Engl. 2014 Nov 17;53(47):12960-5. HOT PAPER

  • Wiedmann RM et al. The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1. In: Cancer Res. 2012 Nov 15;72(22):5976-87.

  • Hoffmann, F et al. A novel technique for selective NF-kappaB inhibition in Kupffer cells: contrary effects in fulminant hepatitis and ischaemia-reperfusion. In: Gut 58(12), 2009. S. 1670-1678. Epub 2009 May 25.

  • Rudy, A et al. Role of Smac in cephalostatin-induced cell death. In: Cell Death Differ. 15(12), 2008. S. 1930-1940. Epub 2008 Sep 19.

  • Schyschka, L et al. Spongistatin 1: a new chemosensitizing marine compound that degrades XIAP. In: Leukemia 22(9), 2008. S. 1737-1745. Epub 2008 Jun 12.

Complete list of publications

Selected projects

  • "Exploiting the Potenatial of Natural Compounds": Myxobacteria as Source for Therapeutical Leads and Chemical Tools in Cancer Research (

  • Apoptosis Signalling induced by Natural Compounds

  • CDK-5 – a novel target in endothelial and tumour biology

  • Tumor targeting via Nanoparticles (NIM – Exzellenz Cluster Munich)

Membership in scientific bodies/juries

  • Member of the scientific committee of the Helmholtz Institute for Infektiology (HZI), since 2014

  • Member of the scientific committee of DECHEMA, since 2014

  • Spokesperson of DFG Research Unit FOR 1406, since 2011

  • Member of the NIM Excellence Cluster Munich, since 2010

  • Member of the executive committee and senate of the DFG, 2007 – 2013

  • Member of the DFG senate committee for clinical research, 2006 – 2012

  • Mentor for the Helmholtz Academy, 2010 – 2014

  • Member of the committee of the Dr Mildred Scheel Foundation for Cancer Research, since 2010

  • Chair of the advisory board to the Robert Bosch hospital and Institute of Clinical Pharmacology, since 2009

  • Member of the committee of the Robert Bosch Foundation, since 2009

  • Spokesperson of the Munich Centre for System-Based Drug Research, since 2009

  • Review board member for the German Research Foundation (DFG), Medicine section, 2004 – 2007

  • Mentor for the LMU excellence programme, 2007 – 2010

  • Liaison to students from the Cusanuswerk (Catholic organisation for the promotion of young talent), 2003-2011

  • Member of the committee of the Dr August and Dr Anni Lesmüller Foundation, 2001 – 2009

  • Member of the German Pharmacopoeia Commission, 2001 – 2005

  • Director of the Department of Pharmacy, LMU Munich, Germany, 2000 – 2002 and 2012 – 2014

Soft Skills/Other activities and achievements

Soft Skills

  • mother of a son (born 1998)


You can only see the contact information of the academics in the database if you are a registered user of AcademiaNet.
Please register here


  1. Read what our members say about AcademiaNet.

No more excuses!

  1. Please download the brochure "No more excuses" and read more about female experts in Europe, and about AcademiaNet.

Similar profiles

  1. Prof. Dr. Amparo Acker-Palmer

    Biological and related sciences , HealthCell Biology, Cellular and Molecular Neuroscience, Vascular Biology, Tumour Biology

  2. Prof. Avan Aihie Sayer

    HealthAcademic Medicine

  3. PhD My Andersson

    Biological and related sciences , HealthNeurophysiology (synaptic physiology)

  4. Dr. Irene Agyepong

    HealthPublic Health



  1. Regulator of Lymphatic System Identified

    Researchers have identified an important regulatory protein that is essential for the patterning of the lymphatic system. Prof. Angelika Vollmar from the University of Munich was part of this international research collaboration.

  2. Keeping Metastases in Check

    Most cancer deaths are caused by metastases. Presently, tumor metastasis cannot be prevented, but a natural product from bacteria may change this.